Ligand Pharmaceuticals (LGND) Share-based Compensation (2010 - 2026)

Ligand Pharmaceuticals has disclosed Share-based Compensation across 17 years of filings, most recently posting $10.6 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $10.6 million, up 35.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.6 million (up 19.28% YoY), and the FY2025 annual result was $46.8 million, up 14.02% from the prior year.
• Share-based Compensation came in at $10.6 million for Q1 2026 at Ligand Pharmaceuticals, down from $14.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $29.1 million in Q4 2022 to a low of $5.7 million in Q4 2023.
• The 5-year median for Share-based Compensation is $9.5 million (2022), against an average of $10.9 million.
• Across the five-year window, Share-based Compensation surged 180.02% in 2022 and sank 80.37% in 2023, its largest moves.
• Ligand Pharmaceuticals' Share-based Compensation stood at $29.1 million in 2022, then tumbled by 80.37% to $5.7 million in 2023, then jumped by 31.52% to $7.5 million in 2024, then soared by 89.66% to $14.3 million in 2025, then dropped by 25.75% to $10.6 million in 2026.
• The last three Share-based Compensation figures came in at $10.6 million (Q1 2026), $14.3 million (Q4 2025), and $14.7 million (Q3 2025), per Business Quant data.